X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing proceeds will support the advancement of multiple wholly-owned pipeline programs into clinical studies, including FMC-376 for the treatment of advanced solid tumors with KRAS G12C Mutations.
Lead Product(s): FMC-376
Therapeutic Area: Oncology Product Name: FMC-376
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Deerfield Management Company
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 22, 2024
Details:
Under the partnership, Frontier Medicine and Abbvie will collaborate on the research and pre-clinical development of programs directed to novel E3 ligases, and certain immunology and oncology targets.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $1,000.0 million Upfront Cash: Undisclosed
Deal Type: Partnership January 05, 2023
Details:
In preclinical studies, FMC-376 retains potency in the context of receptor tyrosine kinase activation, which is likely a major mechanism of non-response and resistance to prior generation inhibitors that only target inactive (GDP-bound) KRASG12C.
Lead Product(s): FMC-376
Therapeutic Area: Oncology Product Name: FMC-376
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
The study was conducted in preclinical models that are both sensitive (NCI-H358 and MIA PaCa-2) and resistant (NCI-H2122) to first-generation KRASG12C inhibitors (adagrasib and sotorasib). While first-generation inhibitors were less effective in the NCI-H2122 cell line model.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
Under the multi-year collaboration, AbbVie and Frontier will utilize Frontier's proprietary chemoproteomics platform to identify small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $1,100.0 million Upfront Cash: $55.0 million
Deal Type: Collaboration December 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
